HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203.

AbstractBACKGROUND:
A significant increase in the rate of vancomycin-resistant Enterococcus faecium (VREfm) bacteremia at our health service, despite improved infection control, prompted us to investigate the cause.
METHODS:
E. faecium bacteremia (including VREfm) over a 12-year period (1998-2009) was investigated using multilocus sequence typing, antibiotic and antiseptic susceptibility profiles, optical mapping, and whole genome sequencing of historical and recent isolates.
RESULTS:
For 10 years, the rate of bacteremia due to vanB VREfm remained stable and sequence type (ST) 17 was predominant. In 2005, ST203 vancomycin-susceptible E. faecium first appeared at our institution, and from March 2007, coinciding with the appearance of a vanB VREfm ST203, the rate of VRE bacteremia has increased exponentially. Although we found no difference in antiseptic susceptibility or presence of genes encoding putative virulence determinants (esp(Efm), hyl(Efm), and fms genes), comparative genomics revealed almost 500 kb of unique sequence when an ST17 and an ST203 VREfm isolate were compared, suggesting that other genomic factors are responsible for the apparent success of E. faecium.
CONCLUSIONS:
The application of multilocus sequence typing has uncovered the emergence of an epidemic clone of E. faecium ST203 that appears to have acquired the vanB locus and has caused a sustained outbreak of VRE bacteremia.
AuthorsPaul D R Johnson, Susan A Ballard, Elizabeth A Grabsch, Timothy P Stinear, Torsten Seemann, Heather L Young, M Lindsay Grayson, Benjamin P Howden
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 202 Issue 8 Pg. 1278-86 (Oct 15 2010) ISSN: 1537-6613 [Electronic] United States
PMID20812846 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Thienamycins
  • VanB protein, Enterococcus
  • Vancomycin
  • Meropenem
Topics
  • Anti-Bacterial Agents (pharmacology)
  • Australia (epidemiology)
  • Bacteremia (drug therapy, epidemiology, microbiology)
  • Bacterial Proteins (genetics)
  • Bacterial Typing Techniques
  • Communicable Diseases, Emerging (microbiology)
  • Cross Infection (drug therapy, epidemiology, microbiology)
  • Disease Outbreaks
  • Electrophoresis, Gel, Pulsed-Field
  • Enterococcus faecium (classification, drug effects, genetics)
  • Genomics
  • Gram-Positive Bacterial Infections (drug therapy, epidemiology, microbiology)
  • Humans
  • Incidence
  • Meropenem
  • Microbial Sensitivity Tests
  • Phylogeny
  • Thienamycins (therapeutic use)
  • Vancomycin (therapeutic use)
  • Vancomycin Resistance (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: